← Back to headlines
Immunic Secures $400M for Late-Stage MS Trials
Immunic, a biopharmaceutical company, has successfully secured $400 million in funding to advance its late-stage clinical trials for Multiple Sclerosis (MS) treatments.
28 Feb, 20:00 — 28 Feb, 20:00
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
FG approves N9.99bn for HIV medication, cancer treatment equipment
just now
The situation in the "renovated" ER is dangerous - it needs to be immediately reinforced with staff
3m ago
A.P. women’s panel chief calls for multi-stakeholder approach to address teenage pregnancies
13m ago
Trader Joe’s Expands Recall of Frozen Asian Foods Over Glass Risk
19m ago